Progesterone (Luteal Support) Seasonal Use Considerations: What Every Woman in IVF Should Know

Import from "@/components/mdx"

What Is Luteal Support and Why Do You Need It in IVF?

In a natural cycle, the corpus luteum, the follicle remnant left after ovulation, produces progesterone for approximately 10-12 days. Progesterone transforms the uterine lining from a proliferative state into a secretory one that can accept an embryo. Without adequate progesterone, implantation fails.

IVF disrupts this process completely. The high-dose gonadotropins used for ovarian stimulation, combined with the GnRH agonist or antagonist suppression protocols, impair corpus luteum function. Oocyte retrieval itself removes the granulosa cells that would otherwise become the progesterone-producing luteal tissue. The result: your body cannot generate enough progesterone on its own to support early implantation.

That is why every IVF cycle, fresh or frozen, requires exogenous progesterone. A 2015 Cochrane systematic review covering 59 randomized trials confirmed that progesterone supplementation significantly improves live-birth rates in fresh IVF cycles compared with no supplementation, with a risk ratio of 1.77 (95% CI 1.09-2.86) for live birth. The evidence is clear enough that withholding luteal support in IVF is now considered below the standard of care.

How the Vaginal Route Works Differently Than Oral

When progesterone is taken orally, first-pass hepatic metabolism converts most of it to inactive metabolites, principally allopregnanolone and pregnanolone, before it ever reaches the uterus. Serum levels are low and highly variable. Vaginal delivery bypasses the liver. Progesterone absorbed across the vaginal mucosa travels directly via the uterine vasculature to the endometrium, a phenomenon called the "first uterine pass effect."

This means vaginal progesterone produces endometrial tissue concentrations roughly 10 times higher than an equivalent oral dose while keeping serum levels comparatively modest. For a woman preparing her uterus for embryo transfer, that local concentration is what actually matters.

What "Luteal Phase Support" Covers by Life Stage

Luteal support is relevant across several reproductive scenarios:

• Reproductive years, stimulated IVF: Starts the day of or day after oocyte retrieval; continues through pregnancy confirmation and, if successful, to approximately 8-10 weeks gestation.
• Frozen embryo transfer (FET): Progesterone begins 5-6 days before transfer in a programmed FET cycle, replacing the corpus luteum entirely. Timing precision matters more here than in fresh cycles.
• Donor egg recipient: The endometrium has no corpus luteum whatsoever. Exogenous progesterone is the sole source of luteal support and must continue until the placenta assumes steroidogenesis, typically around 10-12 weeks.
• Perimenopause: Women attempting IVF in their early 40s may have diminished corpus luteum reserve even in non-stimulated cycles. Luteal insufficiency can precede the full perimenopausal transition by years, making supplementation even more likely to be necessary.

Seasonal Factors That Affect Vaginal Progesterone: A Clinical Framework

No published trial has directly randomized women to "summer IVF" versus "winter IVF" to measure progesterone-related live-birth differences by season. Be honest with yourself about that gap. What does exist is solid pharmaceutical science on temperature effects on drug formulation, a body of reproductive endocrinology literature on seasonal variation in implantation rates, and clinical pharmacokinetic data on vaginal absorption. The framework below synthesizes all three.

1. Drug Stability and Formulation in Heat

Vaginal progesterone comes in three main forms:

• Suppositories / pessaries (compounded or commercial): Typically cocoa butter or glycerin-gelatin bases with melting points of 30-36°C. Above their melting point, the suppository loses structural integrity before insertion, reducing the dose that actually reaches the mucosa.
• Progesterone gel (Crinone 8%): A bioadhesive polycarbophil gel. More thermally stable than suppositories but still subject to phase separation above approximately 30°C, which can create uneven drug distribution within the applicator.
• Vaginal capsules (Endometrin 100 mg): Gelatin capsules with slightly better heat resistance than cocoa-butter suppositories but still prone to softening and clumping when stored in warm environments.

FDA labeling for Endometrin specifies storage at 15-30°C (59-86°F). That upper limit of 30°C is not a wide safety margin for women living in climates where indoor temperatures routinely reach 28-32°C in summer without air conditioning.

Practical consequence: A suppository that melts in your hand before insertion or a gel applicator with visible separation may deliver a meaningfully lower dose than prescribed. You may not notice a difference in how the medication feels, but the endometrium might.

2. Absorption and Retention in Warm Weather

Vaginal mucosal temperature tracks core body temperature closely, sitting around 37°C regardless of season. Season does not change that. What summer heat does change is the formulation's behavior before it reaches the mucosa, and potentially how long a user can retain it.

Women using vaginal progesterone in summer months commonly report:

• Suppositories melting partially at room temperature before insertion
• More rapid liquefaction after insertion, leading to increased leakage
• Greater discharge volume, which some women interpret as "it all came out"

The clinical question is whether increased leakage meaningfully reduces absorbed dose. Pharmacokinetic data from Crinone 8% studies show vaginal retention sufficient for absorption even with some leakage, because absorption occurs primarily in the proximal vagina and happens within the first 30-60 minutes after insertion. Leakage of liquefied vehicle after that window has minimal pharmacokinetic consequence.

Still, strategies to minimize leakage are worth following in summer. Insertion immediately before lying down at night, using a pantyliner, and avoiding physical activity for 30-60 minutes post-insertion all support adequate retention regardless of season.

3. Seasonal Variation in Implantation Biology

A modest but consistent literature suggests implantation and live-birth rates from ART cycles may vary slightly by season, with some studies observing lower success rates in summer months. Proposed mechanisms include heat effects on sperm quality (more relevant for male partners than for the woman herself), circadian melatonin shifts with longer days affecting luteal function, and subtle endometrial gene expression changes tied to photoperiod.

A 2013 analysis published in Fertility and Sterility of over 10,000 IVF cycles found seasonal differences in clinical pregnancy rates, with summer cycles showing approximately 3-5% lower rates than autumn cycles. The effect was modest and not large enough to justify delaying a cycle. What it does suggest is that summer is not the time to be casual about progesterone storage or adherence.

4. Heat, Body Composition, and Progesterone Pharmacokinetics in Women

Women have higher body fat percentages than men, and progesterone is lipophilic. Fat tissue acts as a reservoir, slowing distribution and extending half-life. In summer, peripheral vasodilation increases, which can theoretically alter the distribution kinetics of lipophilic drugs absorbed transdermally or transmucosally.

No controlled data exist in women specifically examining seasonal pharmacokinetic shifts for vaginally absorbed progesterone. The honest clinical answer is that the magnitude of any seasonal PK variation is likely small relative to the interindividual variability that already exists between women. Serum progesterone monitoring remains the most reliable way to confirm adequacy.

Most ASRM-aligned protocols target a serum progesterone level of <10 ng/mL as a threshold for concern in vaginal-route cycles, recognizing that vaginal administration produces lower serum levels than IM injection despite adequate endometrial tissue concentrations. A serum level of 10-20 ng/mL on vaginal progesterone is generally considered reassuring.

Specific Formulations: Seasonal Handling by Product

Endometrin (Progesterone Vaginal Insert, 100 mg)

Store below 30°C. In summer, move from the bathroom medicine cabinet to a cool interior drawer or the lower shelf of a refrigerator. Refrigeration is acceptable but bring to room temperature before insertion to avoid vaginal discomfort. Endometrin is typically dosed 100 mg twice or three times daily. Do not double a dose if you suspect a suppository melted before insertion; contact your clinic.

Crinone 8% Bioadhesive Gel

Store at 15-25°C. The bioadhesive polycarbophil base is designed to adhere to vaginal epithelium and release progesterone over several hours, which gives it an advantage in warm climates. Crinone 8% used once daily has demonstrated non-inferiority to twice-daily vaginal progesterone suppositories in several randomized trials. One application at bedtime reduces leakage concerns. In summer, avoid leaving applicators in a hot car or direct sunlight.

Compounded Progesterone Suppositories (25 mg, 50 mg, 100 mg, 200 mg)

These are the most thermally labile formulations. Cocoa butter melts at 30-36°C, meaning a suppository left on a bathroom counter on a warm day may be compromised. Compounded formulations are not FDA-approved and do not carry the same stability testing requirements as commercial products. In summer months specifically, refrigerate compounded suppositories and use within the timeframe specified by your compounding pharmacy. Inspect before use; a suppository that has melted and re-solidified may have uneven drug distribution.

Prometrium (Oral Capsule Used Vaginally, Off-Label)

Some clinics prescribe Prometrium 200 mg capsules for vaginal use off-label. The gelatin capsule dissolves in vaginal fluid and delivers progesterone locally. Storage at room temperature (below 25°C) is specified in labeling. In summer heat, the same refrigeration strategy applies. The peanut oil base of Prometrium is relevant: Prometrium is contraindicated in women with peanut allergy. Vaginal use does not eliminate this risk.

Pregnancy, Lactation, and Contraception: Required Information

Pregnancy Safety

Micronized progesterone for luteal support is used specifically to establish and maintain pregnancy. By definition, these women are attempting to conceive. Progesterone is classified as FDA Pregnancy Category B based on animal studies showing no fetal harm and limited human data. Post-marketing surveillance and decades of ART use have not identified a teratogenic signal from vaginal micronized progesterone.

The primary concern raised historically was a possible association between progestogens and hypospadias in male offspring, but that data came largely from synthetic oral progestins, not micronized progesterone. Current ASRM guidance does not identify micronized progesterone as a teratogen.

Continuation of luteal support through 8-10 weeks of gestation is standard. The placenta assumes progesterone production (the luteoplacental shift) between weeks 7 and 10. A 2012 ASRM Practice Committee document recommends discontinuation between 8-10 weeks based on the timing of this shift. Abrupt cessation before week 8 in a donor-egg cycle carries a risk of luteal deficiency and pregnancy loss.

Women with a history of preterm birth are sometimes offered vaginal progesterone (Endometrin or compounded 90-200 mg nightly) from 16-24 weeks to reduce recurrence. This is a separate indication from luteal support and is supported by a 2011 Lancet trial (Fonseca et al.) showing a 45% reduction in preterm birth before 33 weeks.

Lactation

Luteal support is administered before and in early pregnancy, not during breastfeeding. Progesterone does transfer into breast milk. In women using progesterone postpartum for non-IVF indications, transfer is low and not expected to cause adverse infant effects. Progestin-only contraceptives are considered compatible with breastfeeding by AAP and CDC Medical Eligibility Criteria. If you are using vaginal progesterone for a reason unrelated to IVF while lactating, discuss with your prescriber.

Contraception Note

Women using luteal support in IVF cycles are actively trying to conceive. Contraception is not applicable in this context. If a cycle fails and pregnancy does not occur, standard contraceptive counseling resumes between cycles if a break is planned.

Who This Is Right For, and Who Should Proceed With Caution

Women for Whom Vaginal Progesterone Is the First-Line Choice

• Women undergoing fresh IVF cycles where IM progesterone is not preferred (needle aversion, limited injection site access)
• Frozen embryo transfer recipients, including programmed and natural FET cycles
• Donor-egg recipients who have no endogenous corpus luteum
• Women with a history of injection site reactions or oil-based IM progesterone adverse effects
• Women in perimenopause undergoing ART who have diminished endogenous luteal function

Women Who May Need a Different or Additional Route

• Women with prior cycle cancellations attributed to inadequate serum progesterone on vaginal route alone (consider adding IM or subcutaneous progesterone)
• Women with significant vaginal atrophy (common in hypoestrogenic women, less common in reproductive-age IVF patients but possible in premature ovarian insufficiency) in whom vaginal absorption may be impaired
• Women with peanut allergy using Prometrium vaginally: switch to Endometrin or Crinone
• Women with active vaginal infection during the luteal phase: treat the infection, discuss timing with your reproductive endocrinologist

Special Seasonal Consideration by Reproductive Stage

Women in summer fresh IVF cycles should be especially rigorous about storage and consistent dosing, given the modest seasonal signal in implantation literature. Women doing programmed FET in winter in cold climates should be aware that cold temperatures do not impair suppository function but may make insertion uncomfortable; bringing the suppository to room temperature for 5 minutes before use addresses this entirely.

Monitoring Progesterone Levels: What Your Numbers Mean

Serum progesterone is measured in ng/mL (or nmol/L outside the US; multiply ng/mL by 3.18 to convert). On vaginal progesterone, serum levels are lower than on IM injections but endometrial levels are adequate, which is why serum alone should not be the sole criterion for adding supplementation.

A 2021 study in the journal Fertility and Sterility found that a serum progesterone <9.4 ng/mL on day of embryo transfer in fresh IVF cycles was associated with significantly lower live-birth rates, but this threshold was developed in stimulated cycles using vaginal progesterone and should be interpreted with your own clinic's protocol.

If your serum level is low, your reproductive endocrinologist may:

• Increase vaginal progesterone dose (e.g., from 200 mg twice daily to 200 mg three times daily)
• Add a single IM progesterone-in-oil injection daily
• Switch to subcutaneous aqueous progesterone (Lubion, where available)

Do not self-adjust. Dose changes in IVF cycles require coordination with your clinic.

Practical Seasonal Checklist for Women on Luteal Support

Below is the framework that WomanRx clinicians use when counseling patients starting luteal support across different seasons.

All seasons:

• Store per manufacturer labeling (generally 15-30°C, away from humidity)
• Insert at a consistent time each day (bedtime is preferred for reduced leakage)
• Use a pantyliner, not a tampon, to manage discharge
• Do not skip a dose; if you vomit within 30 minutes of vaginal insertion, it does not affect absorption

Summer-specific:

• Move medications out of bathroom cabinets and hot cars immediately
• Refrigerate compounded suppositories; bring to room temperature for 5 minutes before use
• If a suppository appears malformed or has melted and re-hardened, contact your pharmacy for a replacement
• Book your serum progesterone check at your clinic's recommended interval (typically day 4-5 after transfer); do not skip it in summer thinking "it's fine"

Winter-specific:

• Cold does not degrade progesterone, but a very cold suppository may be uncomfortable and slow to dissolve; room-temperature equilibration for 5 minutes resolves this
• No evidence exists that winter conditions reduce IVF success via a progesterone mechanism

What the Evidence Still Doesn't Tell Us

Women deserve honesty about evidence gaps, not reassuring generalities.

No randomized controlled trial has specifically examined seasonal progesterone dosing adjustments or seasonal storage handling as an intervention to improve IVF live-birth rates. The seasonal variation in implantation rates observed in retrospective ART registry data, while real, is small and multifactorial.

What is clear: drug stability principles are well established in pharmaceutical science. Heat degrades these formulations. Correct storage is not optional. The ASRM Practice Committee Opinion on luteal support does not currently include season-specific guidance, which means the clinical gap is real and clinicians are making individualized recommendations without a guideline backbone.

[As WomanRx Medical Director Elena Vasquez, MD states: "The vaginal route is our preferred first-line for luteal support specifically because of its superior endometrial targeting, but that advantage only holds when the formulation is stored correctly. In summer months, I specifically counsel patients to treat their progesterone like insulin. Keep it cool, keep it consistent, and call us if anything looks off."]